Figure 2From: Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivationImmunoblotting and immunoprecipitation evatulations of multi-RTK coactivation in ovarian cancer cell lines and primay tumors. A) Imunoblotting evaluations of EGFR, ERBB2, ERBB4, MET, AXL and p53 expression and/or activation in ovarian cancer cell lines (SKOV3, OVCA429 and ES2), mesothelioma cell line (MESO924, positive control), and Hela cell line (negative control). B) The activation of EGFR, ERBB2, ERBB4, MET, and AXL was validated by immunoprecipitation followed by phosphotyrosine and EGFR, ERBB2, ERBB4, MET, and AXL immunoblotting in ovarian cancer cell lines (SKOV3, OVCA429 and ES2). C) Imunoblotting evaluations of EGFR, ERBB2, ERBB4, MET, and AXL expression and/or activation in ovarian cancer primary frozen tumors (p1-p15). D) The activation of AXL was validated by immunoprecipitation followed by phosphotyrosine and AXL immunoblotting in ovarian cancer primary frozen tumors.Back to article page